logo for medical-weight-loss-guide.com
leftimage for medical-weight-loss-guide.com

Bupropion
(Brand names: Wellbutrin, Budeprion, Buproban, Zyban)

How It Works

Bupropion (brand names Wellbutrin, Budeprion, Buproban, and Zyban) is an antidepressant. It is also used to help people stop smoking. It most likely acts though affecting a nerve signal called norepinephrine. Its effects on this signal are thought to cause weight loss. Bupropion is a relative of diethylpropion (Tenuate), another weight loss medicine.

Pros

Compared to other approaches to help people stop smoking, this medicine prevents weight gain. Studies have shown that Wellbutrin can even produce a extra weight loss of somewhere between 2.2% to 5.1%. It is generally well tolerated. If you also need an antidepressant or treatment to help stop smoking, this drug may help in these areas also.

Cons

Side effects include an increased risk for seizures. An inability to fall asleep (insomnia) and anxiety can also occur. There are only small studies on weight loss using bupropion. This makes it more difficult to make recommendations about its use as a weight loss drug.

Other Comments

In 2 of the 3 studies done on this medicine, a diet was given along with the medicine, and exercise was part of one study. Diet and exercise are the mainstays of weight loss and should be used with weight loss drugs.


Return to Home Page or Weight Loss Drugs.



It is important you discuss any weight loss or exercise plan with your doctor. Only you and your physician can decide what is best for you. Some people have certain conditions that prevent them from doing all exercises, and goal body weights may be different for different people. You need to discuss all these things with your physician before starting any weight loss or exercise program.

This article was written by John Vickery, MD.

References

Ann Intern Med 2005;142:525-531
“Drug therapy of Obesity” UpToDate version 15.3
Treatment Guidelines from The Medical Letter 2003;1:101
Treatment Guidelines from the Medical Letter 2008;6:23-28